share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Cambyz Golestaneh(5.41%),Caissa Capital Management Ltd.(3.63%)

Avalo Therapeutics | SC 13G:超過5%持股股東披露文件-Cambyz Golestaneh(5.41%),Caissa Capital Management Ltd.(3.63%)

2022/05/17 15:45
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息